Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Thyroid hormone sprayed into lungs to fight COVID ARDS? trial pulled before start

NCT ID NCT04725110

Disease control Sponsor: University of Minnesota Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study planned to test whether putting a thyroid hormone (T3) directly into the lungs could help people with severe COVID-19 who need a breathing machine. The goal was to reduce fluid in the lungs and shorten time on a ventilator. However, the trial was withdrawn before any patients were enrolled, so no data was collected.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
T3 (thyroid hormone) instilled directly into the lungs
What this could lead to
If it worked, this could point toward a new way to reduce lung fluid and improve breathing in severe COVID-19 patients on ventilators.
What could go wrong
The trial was withdrawn before enrolling anyone, so no results exist. The approach is experimental and unproven in humans for this condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Oct 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Exclusion Criteria: * Pregnancy Inclusion Criteria: * Diagnosis of SARS-CoV-2 with first positive test within 14 days, and, * Diagnosis of ARDS by the Berlin Criteria (2012): 1. Onset: \< 7 days 2. Chest x-ray: Bilateral Patchy Opacities, Infiltrates 3. Mechanical Vent Support: PEEP or CPAP Support \>= 5 cm H2O 4. Pulmonary Edema: Not fully explained by cardiogenic etiology 5. Hypoxia: PaO2/FIO2 Ratio \< 300, or O2Sat/FIO2 Ratio \< 315

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARDS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome adult acute respiratory distress syndrome COVID-19 severe acute respiratory syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARDS ARDS, human COVID19 SARS-CoV infection

Contacts and locations

Locations

  • University of Minnesota

    Minneapolis, Minnesota, 55117, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.